[Inhibitors of protein-tyrosine kinases: pharmacological perspectives?].
Jacquemin-Sablon
A
A
Agbotounou
W K
WK
Pierre
J
J
D000255:Adenosine Triphosphate / Q000378:metabolism; D016227:Benzoquinones; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005419:Flavonoids / Q000494:pharmacology; D019833:Genistein; D006801:Humans; D006873:Hydroquinones / Q000494:pharmacology*; D007529:Isoflavones / Q000494:pharmacology*; D047029:Lactams, Macrocyclic; D010636:Phenols / Q000494:pharmacology*; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011794:Quercetin / Q000494:pharmacology*; D011809:Quinones / Q000494:pharmacology; D017828:Rifabutin / Q000031:analogs & derivatives
D016227:Benzoquinones; D004791:Enzyme Inhibitors; D005419:Flavonoids; D006873:Hydroquinones; D007529:Isoflavones; D047029:Lactams, Macrocyclic; D010636:Phenols; D011809:Quinones; D017828:Rifabutin; C062898:lavendustin A; C020754:herbimycin; D000255:Adenosine Triphosphate; D011794:Quercetin; D019833:Genistein; D011505:Protein-Tyrosine Kinases; C048212:erbstatin
Les inhibiteurs de protéine-tyrosine kinases: perspectives pharmacologiques?